2024/07/12 更新

写真a

ヤマダ ミホコ
山田 美保子
YAMADA Mihoko
所属
医学部附属病院 消化器・腫瘍外科(肝胆膵) 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 博士(医学) ( 2018年3月   名古屋大学 ) 

研究キーワード 1

  1. 肝胆膵外科学

研究分野 1

  1. ライフサイエンス / 消化器外科学

経歴 1

  1. 名古屋大学   医学部附属病院 消化器・腫瘍外科(肝胆膵)   助教

    2024年7月 - 現在

学歴 1

  1. 金沢大学   医学部

    2001年4月 - 2007年3月

受賞 1

  1. 学会賞

    2023年6月   日本肝胆膵外科学会  

 

論文 2

  1. Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma

    Yamada, M; Mizuno, T; Yamaguchi, J; Yokoyama, Y; Igami, T; Onoe, S; Watanabe, N; Uehara, K; Matsuo, K; Ebata, T

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES   29 巻 ( 7 ) 頁: 768 - 777   2022年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Hepato-Biliary-Pancreatic Sciences  

    Background: Clinical tumor staging is essential information for making a therapeutic decision in cancer. This study aimed to identify the optimal tumor classification system for predicting resectability and survival probability in perihilar cholangiocarcinoma. Methods: Patients who were treated for perihilar cholangiocarcinoma between 2009 and 2018 were enrolled. Local tumor extension was staged radiologically according to a diameter-based classification system in addition to the AJCC, Blumgart, and Bismuth systems. Survival and resectability were compared between T subgroups, and the discriminability of the four systems was assessed with Harrell’s concordance index (C-index). Results: Among 702 study patients, 559 (80.0%) underwent laparotomy, 489 (70.0%) of whom underwent resection. The resectability significantly decreased for more advanced tumors in all systems (P <.001); the AJCC system had the greatest discriminability for resectability (area under the curve 0.721). Overall survival at 5 years was 69.9% for AJCC cT1, 45.8% for cT2, 31.8% for cT3, and 15.3% for cT4 tumors (cT1 vs cT2; P =.002, cT2 vs cT3; P =.008 and cT3 vs cT4; P <.001). The AJCC system had the largest C-index of 0.627. Conclusions: The AJCC T system was the optimal classification system for predicting resectability and survival in perihilar cholangiocarcinoma.

    DOI: 10.1002/jhbp.1066

    Web of Science

    Scopus

    PubMed

  2. Pulmonary Metastasis After Resection of Cholangiocarcinoma: Incidence, Resectability, and Survival

    Yamada, M; Ebata, T; Yokoyama, Y; Igami, T; Sugawara, G; Mizuno, T; Yamaguchi, J; Nagino, M

    WORLD JOURNAL OF SURGERY   41 巻 ( 6 ) 頁: 1550 - 1557   2017年6月

     詳細を見る

    記述言語:英語   出版者・発行元:World Journal of Surgery  

    Background: There are few reports on pulmonary metastasis from cholangiocarcinoma; therefore, its incidence, resectability, and survival are unclear. Methods: Patients who underwent surgical resection for cholangiocarcinoma, including intrahepatic, perihilar, and distal cholangiocarcinoma were retrospectively reviewed, and this study focused on patients with pulmonary metastasis. Results: Between January 2003 and December 2014, 681 patients underwent surgical resection for cholangiocarcinoma. Of these, 407 patients experienced disease recurrence, including 46 (11.3%) who developed pulmonary metastasis. Of these 46 patients, 9 underwent resection for pulmonary metastasis; no resection was performed in the remaining 37 patients. R0 resection was achieved in all patients, and no complications related to pulmonary metastasectomy were observed. The median time to recurrence was significantly longer in the 9 patients who underwent surgery than in the 37 patients without surgery (2.5 vs 1.0 years, p < 0.010). Survival after surgery for primary cancer and survival after recurrence were significantly better in the former group than in the latter group (after primary cancer: 66.7 vs 0% at 5 years, p < 0.001; after recurrence: 40.0 vs 8.7% at 3 years, p = 0.003). Multivariate analysis identified the time to recurrence and resection for pulmonary metastasis as independent prognostic factors for survival after recurrence. Conclusion: Resection for pulmonary metastasis originating from cholangiocarcinoma can be safely performed and confers survival benefits for select patients, especially those with a longer time to recurrence after initial surgery.

    DOI: 10.1007/s00268-017-3877-y

    Web of Science

    Scopus

    PubMed

科研費 1

  1. 膵頭十二指腸切除術における周術期QOL変化の解明と治療介入によるQOL改善の応用

    研究課題/研究課題番号:24K19411  2024年4月 - 2029年3月

      詳細を見る

    膵頭十二指腸切除術後は、高い合併症率や栄養吸収障害などから骨格筋量の低下や身体機能の低下といったサルコペニアに陥りやすい。これらの身体的変化は、患者の生活の質quality of life (QOL)の低下と密接に関連し、術後補助化学療法の施行が困難となったり、高齢者では日常生活動作の低下をきたす。術後のQOL変化を正確に把握し、その回復を促すことは生命予後の改善につながる。この研究の目的は、膵頭十二指腸切除術の周術期のQOL変化と身体機能や栄養状態の変化との関連を明らかにすることである。さらに術後の実態をふまえ、術後QOLの回復と維持を目指した、運動・栄養療法による介入研究を行う。